Moderna Therapeutics
VerifiedProvides a real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease
Launch date
Employees
Ownership
Market cap
$56.8b
Net debt
($20b)
Firm valuation
$41.9b (Public information from 2022)
Share price
$142.85 MRNA
Cambridge Massachusetts (HQ)
Deals in current and previous year:
RELATED LANDSCAPES AND LISTS
Financials
Edit| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 135m | 60m | 803m | 18.5b | 21.5b |
| % growth | - | - | - | (56 %) | 1238 % | 2200 % | 16 % |
| EBITDA | - | - | (388m) | (515m) | (732m) | 12.6b | 13.8b |
| % EBITDA margin | - | - | (287 %) | (858 %) | (91 %) | 68 % | 64 % |
| Profit | - | - | (402m) | (514m) | (747m) | 12.2b | 11.4b |
| % profit margin | - | - | (298 %) | (857 %) | (93 %) | 66 % | 53 % |
| EV / revenue | - | - | 32.6x | 92.1x | 45.9x | 5.6x | 1.9x |
| EV / EBITDA | - | - | -11.3x | -10.8x | -50.3x | 4.1x | 3.0x |
| R&D budget | - | - | 307m | 427m | - | - | - |
| R&D % of revenue | - | - | 227 % | 711 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| $40m | Late VC | ||
| $24.6m | Grant | ||
| N/A | $110m | Late VC | |
| $25m | Late VC | ||
| $450m Valuation: $3.0b | Late VC | ||
| $20m | Grant | ||
| N/A | $474m | Growth Equity VC | |
* | $500m Valuation: $7.5b | Series G | |
| $125m | Series H | ||
| N/A | $604m Valuation: $7.5b | IPO | |
| $430m | Grant | ||
| $53m | Grant | ||
| $472m | Grant | ||
| $1.5b | Grant | ||
| $1.7b | Grant | ||
| Total Funding | $5.9b | ||
Recent News about Moderna Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
